Krystal Biotech vs Protagonist Therapeutics
Krystal Biotech (KRYS), health care, and Protagonist Therapeutics (PTGX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Krystal Biotech is worth $8.8B on the stock market and Protagonist Therapeutics $8.1B: Krystal Biotech is valued at 9% more. Krystal Biotech trades at 40.6 times earnings and Protagonist Therapeutics at 26.4; operating margins in their latest fiscal years were 41.5% and -344%. Over the past year Krystal Biotech's share price has moved +45.5% and Protagonist Therapeutics's +47.9%.
Key facts
- Krystal Biotech market value
- $8.8B
- Protagonist Therapeutics market value
- $8.1B
- Krystal Biotech P/E
- 40.6
- Protagonist Therapeutics P/E
- 26.4
- Krystal Biotech revenue
- $389.1MFY to 2025-12-31
- Protagonist Therapeutics revenue
- $46MFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Krystal Biotech | Protagonist Therapeutics |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $8.8Bhigher | $8.1Blower |
| Revenue | $389.1Mhigher | $46Mlower |
| Earnings | $204.8Mhigher | -$130.1Mlower |
| Employees | 295higher | 149lower |
| Total assets | $1.3Bhigher | $668.2Mlower |
| Valuation | ||
| P/E | 40.6higher | 26.4lower |
| P/S | 22.7lower | 177higher |
| P/B | 6.2lower | 7.5higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 41.5%higher | -344%lower |
| Balance sheet | ||
| Net assets | $1.2Bhigher | $614.7Mlower |
| Total liabilities | $114.2Mhigher | $53.5Mlower |
| Total debt | — | — |
| Cash on hand | $496.3Mhigher | $128.4Mlower |
| Price change | ||
| Today | +0.22%higher | -0.13%lower |
| 1 year | +45.5%lower | +47.9%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Krystal Biotech only (0)
None of the tracked investors.
Protagonist Therapeutics only (3)
- Andrew Spokes4.7%
- Stanley Druckenmiller0.6%
- Polen Capital team<0.1%
Percentages are each holding's share of that investor's reported portfolio. · Who owns PTGX
More on Krystal Biotech
Further comparisons
Krystal Biotech against its closest peers
Protagonist Therapeutics against its closest peers
Learn
Questions and answers
Which is bigger, Krystal Biotech or Protagonist Therapeutics?
By market value, Krystal Biotech is the larger: $8.8B against $8.1B for Protagonist Therapeutics. By revenue in its latest fiscal year, Krystal Biotech is the larger: $389.1M against $46M for Protagonist Therapeutics.
Which has the higher P/E ratio?
Krystal Biotech: 40.6, against 26.4 for Protagonist Therapeutics. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Krystal Biotech: 41.5%, against -344% for Protagonist Therapeutics. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which superinvestors own both Krystal Biotech and Protagonist Therapeutics?
None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Krystal Biotech and 3 hold Protagonist Therapeutics.
Cite this page
Funkfolio, “Krystal Biotech vs Protagonist Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/krys-vs-ptgx
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.